Month: April 2021

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MISSISSAUGA, Ontario, April 13, 2021 (GLOBE NEWSWIRE) — goeasy Ltd. (TSX: GSY), (“goeasy” or the “Company”), a leading full-service provider of goods and alternative financial services, announced today that it has entered into an amended agreement with a syndicate of underwriters (the “Underwriters”) led by BMO Capital Markets to increase the size of its previously announced bought deal equity offering of subscription receipts to aggregate gross proceeds of approximately $150 million, representing 1,221,100 subscription receipts (the “Subscription Receipts”), at a price of $122.85 per Subscription Receipt (the “Offering”), to finance a portion of the purchase price for its previously announced acquisition (the “Acquisition”) of LendCare...

RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) — Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing. CEO Lori Woods said Fort’s appointment adds key expertise. “I am very excited to welcome Donna to the Isoray team. Donna brings some twenty-five years of experience in driving increased company revenue and in building and leading sales and marketing teams. Donna also brings a keen understanding of radiation therapy sequencing, and combination therapy with oncologic agents including immunotherapy to her role at Isoray.” Woods concluded, “We believe Donna’s proven dedication to optimizing corporate success will make a valuable contribution as we continue to pursue opportunities to expand Cesium-131...

Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint  Extended protection achieved over several hours Preliminary preclinical data suggest therapeutic utility post SARS-CoV-2 infection Product launch under BentrioTM brand in selected European countries towards end of Q2 2021 Hamilton, Bermuda, April 13, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today provided an update on its AM-301 program for protection against airborne viruses and allergens. “We are very pleased to report on major progress with our AM-301 nasal spray program, which is moving in large steps forward towards the start of commercialization”,...

PALO ALTO, Calif., April 13, 2021 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (NASDAQ: BBIO), and the University of California, San Diego (UC San Diego) today announced a partnership to translate research in genetically driven conditions into potential therapeutic applications for patients, with a focus on oncology and neurology. “UC San Diego is a leading research institution with a top pharmacology department and a strong profile in neurology and oncology. By leveraging their expertise through our collaboration partnership, we hope to advance discoveries into potential treatments as quickly and safely as possible,” said BridgeBio founder and CEO Neil Kumar, Ph.D. Under this partnership, BridgeBio and UC San Diego will collaborate on identifying research programs with strong potential for therapeutic applications that address areas...

中国苏州和美国旧金山, April 13, 2021 (GLOBE NEWSWIRE) — 天演药业（以下简称“公司”或“天演”）（纳斯达克股票代码：ADAG）是一家平台驱动的临床阶段生物制药公司，致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。公司今日宣布在今年的美国癌症研究协会（AACR）年会上公布其第一个安全抗体（SAFEbody™）项目ADG126的临床前数据。 “靶向CTLA-4的疗法存在很多安全性问题，既安全又有效的新型抗CTLA-4疗法是目前重要的临床未满足需求。ADG126现有的数据让我们相信，它有潜力克服与该靶点相关的严重免疫不良反应，” 天演药业联合创始人、首席执行官兼董事长罗培志博士表示，“凭借安全抗体平台技术，我们可以精准且高效地屏蔽抗体与抗原结合域，使抗体仅在肿瘤微环境（TME）中被特异性激活，我们的临床前数据也突出展示了该疗法的有效性和应用前景，ADG126在有效剂量水平下保持了优异的系统安全性，显著提高了治疗指数（TI）。正在进行的全球I期试验有望为我们的安全抗体平台及安全抗体项目ADG126提供临床验证。我们已成功完成了0.1 mg/kg剂量下3名患者的安全性（剂量限制性毒性DLT）评估，并按计划预计于2021年下半年公布初步安全性和有效性的研究数据。” 目前，可通过AACR官网访问标题为“A Novel Anti-CTLA-4 Checkpoint Inhibitor Prodrug to Address On-target Off-tumor Toxicity for Cancer Immunotherapy”的壁报，该壁报也可在天演药业官网（www.adagene.com）下载。 报告摘要如下：主要结论：ADG126在临床前研究中展示了优异的安全性及强大的抗肿瘤疗效。 具有跨物种交叉反应的抗原表位：ADG126针对CTLA-4抗原的保守表位，并具有多物种交叉反应，可作为抗体前药（prodrug）被激活，在多种免疫功能健全的小鼠肿瘤模型中显示了单一和联合抗肿瘤疗效。 高度差异化的作用机理：与伊匹单抗（ipilimumab）相比，激活的ADG126具有更柔性的配体阻断，在肿瘤微环境中也表现出更强的抗体依赖细胞介导毒作用...

SAN FRANCISCO and SUZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced updated preclinical data from its lead SAFEbody™ program, ADG126, are being presented at the American Association for Cancer Research (AACR) Annual Meeting 2021. “There is a critical unmet need for new anti-CTLA-4 therapies, and we are encouraged by the data generated to date, which demonstrate ADG126 has the potential to overcome the severe immune-mediated adverse reactions associated with the class,” said Peter Luo, Ph.D., Co-founder, Chief Executive Officer and Chairman of Adagene. “By leveraging our SAFEbody platform technology, designed to precisely...